Universe Pharmaceuticals (NASDAQ:UPC) & Chugai Pharmaceutical (OTCMKTS:CHGCY) Head-To-Head Comparison

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Universe Pharmaceuticals (NASDAQ:UPC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chugai Pharmaceutical and Universe Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	34.98%	22.90%	19.45%
Universe Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Chugai Pharmaceutical and Universe Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	1	0	2	3.33
Universe Pharmaceuticals	1	0	0	0	1.00

Risk & Volatility

Chugai Pharmaceutical has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Valuation and Earnings

This table compares Chugai Pharmaceutical and Universe Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	9.35	$2.91 billion	$0.90	26.54
Universe Pharmaceuticals	$17.86 million	0.10	-$3.67 million	N/A	N/A

Chugai Pharmaceutical has higher revenue and earnings than Universe Pharmaceuticals.

Summary

Chugai Pharmaceutical beats Universe Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Universe Pharmaceuticals

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji’An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.